Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
LXEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.45 - $11.72
Previous CloseN/A
Volume22.32K
Average Volume (3M)387.19K
Market Cap
$289.45M
Enterprise Value$51.19M
Total Cash (Recent Filing)$132.89M
Total Debt (Recent Filing)$8.91M
Price to Earnings (P/E)―
Beta2.22
Next Earnings
Dec 15, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding54,001,213
10 Day Avg. Volume561,789
30 Day Avg. Volume387,188
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue26.33
Enterprise Value/Gross Profit-93.41
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$14.60Price Target Upside167.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Competitive PositioningLexeo appears poised to outperform PKP2 gene therapy rivals as LX2020 readout approaches.
Financial PositionLXEO ended the period with $152.5mm in cash and equivalents, expected to fund future developments.
Strategic CollaborationsLXEO announced a $80mm private placement and research collaboration to advance non-viral, RNA-based therapeutics for cardiac genetic disease.
Bears Say
Price Target AdjustmentThe price target for LXEO was reduced from $10 to $9.
Regulatory ChallengesLXEO is seen as well-positioned compared to gene therapy peers despite regulatory uncertainty.
Lexeo Therapeutics, Inc. News
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $1.45 and its highest was $11.72 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $289.45M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Dec 15, 2025 which is in 86 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.679 by $0.079.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 54,001,213 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.679. Following the earnings report the stock price went up 1.483%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
Lexeo Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (167.40% Upside)
$14.60 (167.40% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $33.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.00%
12-Months-Change
Fundamentals
Return on Equity
-75.32%
Trailing 12-Months
Asset Growth
-8.30%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
LXEO Stock 12 Month Forecast
Average Price Target
$14.60
▲(167.40% Upside)
Technical Analysis
Biomea Fusion
―
Unicycive Therapeutics
―
Acumen Pharmaceuticals
―
Invivyd
―
Genenta Science SpA Sponsored ADR
―
Ownership Overview
1.09% Insiders
6.20% Mutual Funds
37.82% Other Institutional Investors
48.78% Public Companies and
Individual Investors